Ghrelin: A molecular target for weight regulation, glucose and lipid metabolism

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 2, Issue 3, 2008, Pages 178-193

  Prodam, Flavia ^a   Bellone, Simonetta ^a   Corneli, Ginevra ^a   Golisano, Grazielle ^a   Bona, Gianni ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Acylated ghrelin; Diabetes; Food intake; Ghrelin; GHS receptor; Glucose; Insulin secretion; Lipid metabolism; Metabolism; Obesity; Unacylated ghrelin; Wasting syndrome

Indexed keywords

2 METHYLALANYL DEXTRO TRYPTOPHAN 1 FORMAMIDO 2 (3 INDOLYL)ETHYLAMIDE; 2,4 DIMETHOXYBENZYLPHENETHYL(PYRIDINE 2 YL)CARBOXYLTRIAZOLE; 3 (2 HYDROXYPROPYLAMINO) 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; BIM 28163; CAPROMORELIN; GHRELIN; GHRELIN ANTIBODY; GHRELIN RECEPTOR; GLUCOSE; GROWTH HORMONE SECRETAGOGUE RECEPTOR 1A STIMULATING AGENT; HEXARELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; HORMONE RECEPTOR AFFECTING AGENT; IBUTAMOREN; INSULIN; IPAMORELIN; JMV 2806; JMV 2844; JMV 2951; JMV 3008; L 692400; LIPID; LY 44471; METENKEPHALIN[2 DEXTRO TRYPTOPHAN]; MONOCLONAL ANTIBODY; PRALMORELIN; SM 130686; TABIMORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACYLATION; ATHEROGENESIS; CACHEXIA; CLINICAL TRIAL; DIABETES MELLITUS; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENERGY BALANCE; FEEDING; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; HORMONE ACTION; HORMONE RELEASE; HORMONE STRUCTURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATENT; PRADER WILLI SYNDROME; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ROUX Y ANASTOMOSIS; STOMACH BYPASS; WASTING SYNDROME; WEIGHT CONTROL; WEIGHT REDUCTION;

EID: 58149129514     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221408786241766     Document Type: Review

References (198)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
2. Caballero B. A nutrition paradox - underweight and obesity in developing countries. N Engl J Med 2005; 352: 1514-1516.
3. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291: 2847-2850.
4. Walley AJ, Blakemore AI, Froguel P. Genetics of obesity and the prediction of risk for health. Hum Mol Genet 2006; 15: R124-R130.
5. Maffeis C, Tato L. Long-term effects of childhood obesity on morbidity and mortality. Horm Res 2001; 55(1): 42-45.
6. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602.
7. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350.
8. Broglio F, Prodam F, Martina V, Benso A. Metabolic actions of ghrelin. Obes Metab 2006; 2:172-183.
9. Gil-Campos M, Aguilera CM, Canete R, Gil A. Ghrelin: a hormone regulating food intake and energy homeostasis. Br J Nutr 2006; 96: 201-226.
10. McNay EC. Insulin and ghrelin: peripheral hormones modulating memory and hippocampal function. Curr Opin Pharmacol 2007; 7: 628-632.
11. Chaudhri OB, Wynne K, Bloom SR. Can gut hormones control appetite and prevent obesity? Diabetes Care 2008; 31 (2): S284-S289.
12. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008; 18: 158-168.
13. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
14. van Der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-457.
15. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol 2004; 25: 27-68.
16. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
17. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-977.
18. Ghigo E, Arvat E, Giordano R, et al. Biologic activities of growth hormone secretagogues in humans. Endocrine 2001; 14: 87-93.
19. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab 2001; 86: 1464-1469.
20. Silva EMV, Bednarek MA, Gao YD. 1H NMR structural analysis of human ghrelin and its six truncated analogs. Biopolymers 2001; 59: 489-501.
21. Matsumoto M, Hosoda H, Kitajima Y, et al. Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun 2001; 287: 142-146.
22. Hosoda H, Kojima M, Matsuo H, Kangawa K. Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J Biol Chem 2000; 275: 21995-22000.
23. Gauna C, Meyler FM, Janssen JA, et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 2004; 89: 5035-5042.
24. Broglio F, Prodam F, Riganti F. The continuous infusion of acylated ghrelin enhances GH secretion and worsen glucose metabolism in humans. J Endocrinol Invest 2008 (in press).
25. Broglio F, Gottero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004; 89: 3062-3065.
26. Gauna C, Delhanty PJ, Hofland LJ, et al. Ghrelin stimulates, while des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 2005; 90: 1055-1060.
27. Wiedmer P, Nogueiras R, Broglio F, D'Alessio D, Tschop MH. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 705-712.
28. Gauna C, van de ZB, van KA, Themmen AP, van Der Lely AJ, Delhanty PJ. Unacylated ghrelin is not a functional antagonist but a full agonist of the type 1a growth hormone secretagogue receptor (GHS-R). Mol Cell Endocrinol 2007; 274: 30-34.
29. Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008; 132: 387-396.
30. Vivenza D, Rapa A, Castellino N, et al. Ghrelin gene polymorphisms and ghrelin, insulin, IGF-I, leptin and anthropometric data in children and adolescents. Eur J Endocrinol 2004; 151: 127-133.
31. Ukkola O, Ravussin E, Jacobson P, et al. Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. J Clin Endocrinol Metab 2001; 86: 3996-3999.
32. Steinle NI, Pollin TI, O'Connell JR, Mitchell BD, Shuldiner AR. Variants in the ghrelin gene are associated with metabolic syndrome in the Old Order Amish. J Clin Endocrinol Metab 2005; 90: 6672-6677.
33. Larsen LH, Gjesing AP, Sorensen TI, et al. Mutation analysis of the preproghrelin gene: no association with obesity and type 2 diabetes. Clin Biochem 2005; 38: 420-424.
34. Zhang JV, Ren PG, Vsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-999.
35. Soares JB, Leite-Moreira AF. Ghrelin, des-acyl ghrelin and obestatin: Three pieces of the same puzzle. Peptides 2008; 29: 1255-1270.
36. Gourcerol G, St-Pierre DH, Tache Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Regul Pept 2007; 141: 1-7.
37. Nogueiras R, Pfluger P, Tovar S, et al. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology 2007; 148: 21-26.
38. Zhang JV, Jahr H, Luo CW, et al. Obestatin induction of early response gene expression in gastrointestinal and adipose tissues and the mediatory role of GPR39. Mol Endocrinol 2008; 22: 1464-1475.
39. Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W. Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 2006; 351: 21-25.
40. Seoane LM, Al-Massadi O, Pazos Y, Pagotto U, Casanueva FF. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 2006; 29: RC13-RC15.
41. Tang SQ, Jiang QY, Zhang YL, et al. Obestatin: Its physicochemical characteristics and physiological functions. Peptides 2008; 29: 639-645.
42. Kobelt P, Wisser AS, Stengel A, et al. Peripheral obestatin has no effect on feeding behavior and brain Fos expression in rodents. Peptides 2008; 29: 1018-1027.
43. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988-2991.
44. Chanoine JP, Wong AC. Ghrelin gene expression is markedly higher in fetal pancreas compared with fetal stomach: effect of maternal fasting. Endocrinology 2004; 145: 3813-3820.
45. Wierup N, Svensson H, Mulder H, Sundler F. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept 2002; 107: 63-69.
46. Wierup N, Yang S, McEvilly RJ, Mulder H, Sundler F. Ghrelin is expressed in a novel endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832/13) cells. J Histochem Cytochem 2004; 52: 301-310.
47. Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and desacyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000; 279: 909-913.
48. Hosoda H, Kojima M, Mizushima T, Shimizu S, Kangawa K. Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J Biol Chem 2003; 278: 64-70.
49. Vestergaard ET, Hansen TK, Gormsen LC, et al. Constant intravenous ghrelin infusion in healthy young men: Clinical pharmacokinetics and metabolic effects. Am J Physiol Endocrinol Metab 2007; 293: H3020-3026.
50. De Vriese C, Gregoire F, Lema-Kisoka R, Waelbroeck M, Robberecht P, Delporte C. Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology 2004; 145: 4997-5005.
51. Beaumont NJ, Skinner VO, Tan TM, et al. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 2003; 278: 8877-8880.
52. Vartiainen J, Poykko SM, Raisanen T, Kesaniemi YA, Ukkola O. Sequencing analysis of the ghrelin receptor (growth hormone secretagogue receptor type 1a) gene. Eur J Endocrinol 2004; 150: 457-463.
53. Chan CB, Cheng CH. Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Acanthopagrus schlegeli. Mol Cell Endocrinol 2004; 214: 81-95.
54. Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006; 89: 71-84.
55. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 2004; 101: 4679-4684.
56. Leite-Moreira AF, Soares JB. Physiological, pathological and potential therapeutic roles of ghrelin. Drug Discov Today 2007; 12: 276-288.
57. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High constitutive signaling of the ghrelin receptor - identification of a potent inverse agonist. Mol Endocrinol 2003; 17: 2201-2210.
58. Holst B, Mokrosinski J, Lang M, et al. Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem 2007; 282: 15799-15811.
59. Pantel J, Legendre M, Cabrol S, et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 2006; 116: 760-768.
60. Wang HJ, Geller F, Dempfle A, et al. Ghrelin receptor gene: identification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students, and children with short normal stature. J Clin Endocrinol Metab 2004; 89: 157-162.
61. Halem HA, Taylor JE, Dong JZ, et al. A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology 2005; 81: 339-349.
62. Muccioli G, Pons N, Ghe C, Catapano F, Granata R, Ghigo E. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 2004; 498: 27-35.
63. Cassoni P, Ghe C, Marrocco T, et al. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol 2004; 150: 173-184.
64. Dehlin E, Liu J, Yun SH, et al. Regulation of ghrelin structure and membrane binding by phosphorylation. Peptides 2008; 29: 904-911.
65. Toshinai K, Yamaguchi H, Sun Y, et al. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 2006; 147: 2306-2314.
66. Muccioli G, Baragli A, Granata R, Papotti M, Ghigo E. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology 2007; 86: 147-164.
67. Broglio F, Prodam F, Me E, et al. Ghrelin: endocrine, metabolic and cardiovascular actions. J Endocrinol Invest 2005; 28: 23-25.
68. Demers A, Rodrigue-Way A, Tremblay A. Hexarelin Signaling to PPARgamma in Metabolic Diseases. PPAR Res 2008; 2008: 364784.
69. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-4758.
70. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
71. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-709.
72. Perreault M, Istrate N, Wang L, Nichols AJ, Tozzo E, Stricker-Krongrad A. Resistance to the orexigenic effect of ghrelin in dietary-induced obesity in mice: reversal upon weight loss. Int J Obes Relat Metab Disord 2004; 28: 879-885.
73. Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci USA 2004; 101: 10434-10439.
74. Vazquez RMI, Camilleri M, Stephens DA, et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology 2006; 131: 1717-1724.
75. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002; 87: 2984-2987.
76. Cummings DE, Schwartz MW. Genetics and pathophysiology of human obesity. Annu Rev Med 2003; 54: 453-471.
77. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007; 8: 21-34.
78. Purnell JQ, Cummings D, Weigle DS. Changes in 24-h area-under-the-curve ghrelin values following diet-induced weight loss are associated with loss of fat-free mass, but not with changes in fat mass, insulin levels or insulin sensitivity. Int J Obes 2007; 31: 385-389.
79. Korbonits M, Gueorguiev M, O'Grady E, et al. A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab 2002; 87: 4005-4008.
80. Vartiainen J, Kesaniemi YA, Ukkola O. Sequencing analysis of ghrelin gene 5′ flanking region: relations between the sequence variants, fasting plasma total ghrelin concentrations, and body mass index. Metabolism 2006; 55: 1420-1425.
81. Martin GR, Loredo JC, Sun G. Lack of association of ghrelin precursor gene variants and percentage body fat or serum lipid profiles. Obesity 2008; 16: 908-912.
82. Ando T, Ichimaru Y, Konjiki F, Shoji M, Komaki G. Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women. Am J Clin Nutr 2007; 86: 25-32.
83. Paik KH, Choe YH, Park WH, et al. Suppression of acylated ghrelin during oral glucose tolerance test is correlated with wholebody insulin sensitivity in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2006; 91: 1876-1881.
84. Paik KH, Jin DK, Song SY, et al. Correlation between fasting plasma ghrelin levels and age, body mass index (BMI), BMI percentiles, and 24-hour plasma ghrelin profiles in Prader-Willi syndrome. J Clin Endocrinol Metab 2004; 89: 3885-3889.
85. DelParigi A, Tschop M, Heiman ML, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab 2002; 87: 5461-5464.
86. Goldstone AP, Thomas EL, Brynes AE, et al. Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab 2004; 89: 1718-1726.
87. Bittel DC, Kibiryeva N, Dasouki M, Knoll JH, Butler MG. A 9-year-old male with a duplication of chromosome 3p25.3p26.2: clinical report and gene expression analysis. Am J Med Genet A 2006; 140: 573-579.
88. Kim MS, Yoon CY, Park KH, et al. Changes in ghrelin and ghrelin receptor expression according to feeding status. Neuroreport 2003; 14: 1317-1320.
89. Muller AF, Lamberts SW, Janssen JA, et al. Ghrelin drives GH secretion during fasting in man. Eur J Endocrinol 2002; 146: 203-207.
90. Natalucci G, Riedl S, Gleiss A, Zidek T, Frisch H. Spontaneous 24-h ghrelin secretion pattern in fasting subjects: maintenance of a meal-related pattern. Eur J Endocrinol 2005; 152: 845-850.
91. Avram AM, Jaffe CA, Symons KV, Barkan AL. Endogenous circulating ghrelin does not mediate GH rhythmicity or response to fasting. J Clin Endocrinol Metab 2005; 90: 2982-2987.
92. Espelund U, Hansen TK, Hojlund K, et al. Fasting unmasks a strong inverse association between ghrelin and cortisol in serum: studies in obese and normal-weight subjects. J Clin Endocrinol Metab 2005; 90: 741-746.
93. Liu J, Prudom C, Nass R, et al. Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. J Clin Endocrinol Metab 2008; 93: 1980-1987.
94. Nass R, Farhy L, Liu J, et al. Evidence for acyl-ghrelin modulation of growth hormone release in the fed state. J Clin Endocrinol Metab 2008; 93: 1988-1994.
95. Norrelund H. The metabolic role of growth hormone in humans with particular reference to fasting. Growth Horm IGF Res 2005; 15: 95-122.
96. Prodam F, Me E, Riganti F, et al. The nutritional control of ghrelin secretion in humans: The effects of enteral vs. parenteral nutrition. Eur J Nutr 2006; 45: 399-405.
97. Nishi Y, Hiejima H, Hosoda H, et al. Ingested medium-chain fatty acids are directly utilized for the acyl-modification of ghrelin. Endocrinology 2005; 146: 2709-2715.
98. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschop M, Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 2002; 87: 5625-5629.
99. Langenberg C, Bergstrom J, Laughlin GA, Barrett-Connor E. Ghrelin and the metabolic syndrome in older adults. J Clin Endocrinol Metab 2005; 90: 6448-6453.
100. Erdmann J, Lippl F, Wagenpfeil S, Schusdziarra V. Differential association of basal and postprandial plasma ghrelin with leptin, insulin, and type 2 diabetes. Diabetes 2005; 54: 1371-1378.
101. Broglio F, Gottero C, Van Koetsveld P, et al. Acetylcholine regulates ghrelin secretion in humans. J Clin Endocrinol Metab 2004; 89: 2429-2433.
102. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001; 86: 1169-1174.
103. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
104. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50: 2540-2547.
105. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
106. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50: 227-232.
107. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004; 145: 2607-2612.
108. Shrestha YB, Wickwire K, Giraudo SQ. Role of AgRP on Ghrelin-induced feeding in the hypothalamic paraventricular nucleus. Regul Pept 2006; 133: 68-73.
109. Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003; 52: 947-952.
110. Bagnasco M, Tulipano G, Melis MR, Argiolas A, Cocchi D, Muller EE. Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in response to fasting. Regul Pept 2003; 111: 161-167.
111. Zorrilla EP, Iwasaki S, Moss JA, et al. Vaccination against weight gain. Proc Natl Acad Sci USA 2006; 103: 13226-13231.
112. Kineman RD, Gahete MD, Luque RM. Identification of a mouse ghrelin gene transcript that contains intron 2 and is regulated in the pituitary and hypothalamus in response to metabolic stress. J Mol Endocrinol 2007; 38: 511-521.
113. Kohno D, Nakata M, Maekawa F, et al. Leptin suppresses ghrelin-induced activation of neuropeptide Y neurons in the arcuate nucleus via phosphatidylinositol-3-kinase and phosphodiesterase 3-mediated pathway. Endocrinology 2007; 148: 2251-2263.
114. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120: 337-345.
115. Arnold M, Mura A, Langhans W, Geary N. Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J Neurosci 2006; 26: 11052-11060.
116. Broglio F, Gottero C, Benso A, et al. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans. Clin Endocrinol 2003; 58: 92-98.
117. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006; 116: 1983-1993.
118. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23: 7973-7981.
119. Wortley KE, Anderson KD, Garcia K, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci USA 2004; 101: 8227-8232.
120. Wortley KE, Del Rincon JP, Murray JD, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005; 115: 3573-3578.
121. Asakawa A, Inui A, Fujimiya M, et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005; 54: 18-24.
122. Chen CY, Chao Y, Chang FY, Chien EJ, Lee SD, Doong ML. Intracisternal des-acyl ghrelin inhibits food intake and non-nutrient gastric emptying in conscious rats. Int J Mol Med 2005; 16: 695-699.
123. Barazzoni R, Zanetti M, Ferreira C, et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3935-3940.
124. Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol 2007; 58 (1): 13-35.
125. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630.
126. Cummings DE, Shannon MH. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 2003; 88: 2999-3002.
127. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90: 359-365.
128. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 2008; 16: 298-305.
129. Bertoli S, Magni P, Krogh V, et al. Is ghrelin a signal of decreased fat-free mass in elderly subjects? Eur J Endocrinol 2006; 155: 321-330.
130. Akamizu T, Kangawa K. Emerging results of anticatabolic therapy with ghrelin. Curr Opin Clin Nutr Metab Care 2007; 10:278-283.
131. Hanada T, Toshinai K, Kajimura N, et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 2003; 301: 275-279.
132. Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9: 774-778.
133. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active/total ghrelin ration in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90: 2920-2926.
134. Tacke F, Brabant G, Kruck E, et al. Ghrelin in chronic liver disease. J Hepatol 2003; 38: 447-454.
135. Nagaya N, Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr Opin Pharmacol 2003; 3: 146-151.
136. Misra M, Miller KK, Stewart V, et al. Ghrelin and bone metabolism in adolescent girls with anorexia nervosa and healthy adolescents. J Clin Endocrinol Metab 2005; 90: 5082-5087.
137. Shinomiya T, Fukunaga M, Akamizu T, et al. Plasma acylated ghrelin levels correlate with subjective symptoms of functional dyspepsia in female patients. Scand J Gastroenterol 2005; 40: 648-653.
138. Thompson NM, Gill DA, Davies R, et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 2004; 145: 234-242.
139. Zhang W, Zhao L, Lin TR, et al. Inhibition of adipogenesis by ghrelin. Mol Biol Cell 2004; 15: 2484-2491.
140. Choi K, Roh SG, Hong YH, et al. The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. Endocrinology 2003; 144: 754-759.
141. Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288: E228-E235.
142. Kim MS, Yoon CY, Jang PG, et al. The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes. Mol Endocrinol 2004; 18: 2291-2301.
143. Patel AD, Stanley SA, Murphy KG, et al. Ghrelin stimulates insulin-induced glucose uptake in adipocytes. Regul Pept 2006; 134: 17-22.
144. Tsubone T, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA expression in brown adipose tissue in mice. Regul Pept 2005; 130: 97-103.
145. Giovambattista A, Piermaria J, Suescun MO, Calandra RS, Gaillard RC, Spinedi E. Direct effect of ghrelin on leptin production by cultured rat white adipocytes. Obesity 2006; 14: 19-27.
146. Giovambattista A, Gaillard RC, Spinedi E. Ghrelin gene-related peptides modulate rat white adiposity. Vitam Horm 2008; 77: 171-205.
147. Bassil MS, Mrayati MM, Hwalla NC, Obeid OA. Acute effect of leptin and ghrelin injection on postprandial glycogen and lipid synthesis in rats. Ann Nutr Metab 2007; 51:14-21.
148. Rigault C, Le BF, Georges B, Demarquoy J. Ghrelin reduces hepatic mitochondrial fatty acid beta oxidation. J Endocrinol Invest 2007; 30:RC4-RC8.
149. Rindi G, Necchi V, Savio A, et al. Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochem Cell Biol 2002; 117: 511-519.
150. Volante M, Allia E, Gugliotta P, et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 2002; 87: 1300-1308.
151. Prado CL, Pugh-Bernard AE, Elghazi L, Sosa-Pineda B, Sussel L. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc Natl Acad Sci USA 2004; 101: 2924-2929.
152. Kageyama H, Funahashi H, Hirayama M, et al. Morphological analysis of ghrelin and its receptor distribution in the rat pancreas. Regul Pept 2005; 126: 67-71.
153. Irako T, Akamizu T, Hosoda H, et al. Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats. Diabetologia 2006; 49: 1264-1273.
154. Granata R, Settanni F, Biancone L, et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic {beta} cells and human islets. Involvement of cAMP/PKA, ERK1/2 and PI3K/Akt signaling. Endocrinology 2007; 148: 512-529.
155. Clark RG, Thomas GB, Mortensen DL, et al. Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology 1997; 138: 4316-4323.
156. Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002; 277: 5667-5674.
157. Takahashi H, Kurose Y, Kobayashi S, et al. Ghrelin enhances glucose-induced insulin secretion in scheduled meal-fed sheep. J Endocrinol 2006; 189: 67-75.
158. Reimer MK, Pacini G, Ahren B. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology 2003; 144: 916-921.
159. 2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes 2004; 53: 3142-3151.
160. Egido EM, Rodriguez-Gallardo J, Silvestre RA, Marco J. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur J Endocrinol 2002; 146: 241-244.
161. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083-5086.
162. Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118: 239-249.
163. Broglio F, Gottero C, Benso A, et al. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J Clin Endocrinol Metab 2003; 88: 4268-4272.
164. St-Pierre DH, Karelis AD, Coderre L, et al. Association of acylated and nonacylated ghrelin with insulin sensitivity in overweight and obese postmenopausal women. J Clin Endocrinol Metab 2007; 92: 264-269.
165. Doi A, Shono T, Nishi M, Furuta H, Sasaki H, Nanjo K. IA-2beta, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion. Proc Natl Acad Sci USA 2006; 103: 885-890.
166. Salehi A, de la Cour CD, Hakanson R, Lundquist I. Effects of ghrelin on insulin and glucagon secretion: a study of isolated pancreatic islets and intact mice. Regul Pept 2004; 118: 143-150.
167. Heijboer AC, Van den Hoek AM, Parlevliet ET, et al. Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice. Diabetologia 2006; 49: 732-738.
168. Ariyasu H, Takaya K, Iwakura H, et al. Transgenic mice overexpressing des-acyl ghrelin show small phenotype. Endocrinology 2005; 146: 355-364.
169. Sun Y, Asnicar M, Saha PK, Chan L, Smith RG. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab 2006; 3: 379-386.
170. Dezaki K, Sone H, Koimizu M, et al. Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent hig-fat diet-induced glucose intolerance. Diabetes 2006; 3486-3493.
171. Akamizu T, Murayama T, Teramukai S, et al. Plasma ghrelin levels in healthy elderly volunteers: the levels of acylated ghrelin in elderly females correlate positively with serum IGF-I levels and bowel movement frequency and negatively with systolic blood pressure. J Endocrinol 2006; 188: 333-344.
172. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 2008; 14: 161-168.
173. Tomasetto C, Karam SM, Ribieras S, et al. Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. Gastroenterology 2000; 119: 395-405.
174. Sheppard, P., Deisher, T.:WO9842840 (1998).
175. Benso A, Prodam F, Lucatello B, et al. d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans. Neuropeptides 2007; 41: 45-49.
176. Heiman, M.L., Kikly, K.K., Manetta, J.V., Witcher, D.R.: WO05026211A2 (2005).
177. Kikly, K.K., Manetta, J.V., Witcher, D.R.: WO06019577A1 (2006).
178. Witcher, D.R., Kikly, K.K., Manetta, J.V.: WO060553473A2 (2006).
179. Heiman, M.L., Kikly, K.K., Manetta, J.V., Witcher, D.R.: US20060233788A1 (2006).
180. Kikly, K.K., Manetta, J.V., Witcher, D.R.: US20070237775A1 (2007).
181. Heiman, M.L., Kikly, K.K., Manetta, J.V., Witcher, D.R.: WO0516951A2 (2005).
182. Marquis, D.M., Vasserot, A. P., Witcher, D.R.: WO06091381 (2006).
183. Heiman, M., L.: US20060269550A1 (2006).
184. Boving, T.E.G., Klysner, S.: WO04024183A1 (2004).
185. Mager U, Lindi V, Lindstrom J, et al. Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study. Diabet Med 2006; 23: 685-689.
186. Baessler A, Hasinoff MJ, Fischer M, et al. Genetic linkage and association of the growth hormone secretagogue receptor (ghrelin receptor) gene in human obesity. Diabetes 2005; 54: 259-267.
187. Kuzuya M, Ando F, Iguchi A, Shimokata H. Preproghrelin Leu72Met variant contributes to overweight in middle-aged men of a Japanese large cohort. Int J Obes 2006; 30: 1609-1614.
188. Broglio F, Prodam F, Riganti F, et al. Unacylated ghrelin (UAG) enhances the early insulin response to meal, improves glucose metabolism and decrease free fatty acids levels in healthy volunteers: The Endocrine Society's 89th Annual Meeting, Toronto, Canada (2007).
189. Ghigo, E., van der Lely, A.J.: WO03051389A2 (2003).
190. Ghigo, E., van der Lely, A.J.: WO05039624A2 (2005).
191. Nilsson, H., Lange, B.H., Post, C., Nielsen, T.G.: WO0597173A2 (2005).
192. Schambye, H.T., Lange, B.H., Jensen, P.H.: WO06058539A2 (2006).
193. Dong, Z.X., Eynon, J.S., Shen, Y.: WO07014258A2 (2007).
194. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/ cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008; 98: 300-308.
195. Hoveyeda, H., Peterson, M., Fraser, G., Ramaseshan, M.: WO06009674A1 (2006).
196. Polvino, W.J.: WO06029930A1 (2006).
197. Geesaman, B.J.: EP1781311A2 (2007).
198. Polvino, W.J.: US20070191283A1 (2007).